Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The Potential for Chemotherapy-Free Strategies in Advanced Prostate Cancer.

Cetin B, Ozet A.

Curr Urol. 2019 Oct;13(2):57-63. doi: 10.1159/000499292. Epub 2019 Oct 1. Review.

2.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
3.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
4.

Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.

Pharmacoeconomics. 2017 Apr;35(4):415-424. doi: 10.1007/s40273-016-0457-1. Review.

5.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
6.

Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.

Omlin A, Pezaro C, Gillessen Sommer S.

Ther Adv Urol. 2014 Feb;6(1):3-14. doi: 10.1177/1756287213509677. Review.

7.

Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Kapoor A, Wu C, Shayegan B, Rybak AP.

Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E414-E423. doi: 10.5489/cuaj.4112. Epub 2016 Dec 12. Review.

8.

Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.

Schweizer MT, Antonarakis ES.

Ther Adv Urol. 2012 Aug;4(4):167-78. doi: 10.1177/1756287212452196.

9.

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.

Mukherji D, El Dika I, Temraz S, Haidar M, Shamseddine A.

Ther Clin Risk Manag. 2014 May 23;10:373-80. doi: 10.2147/TCRM.S45667. eCollection 2014. Review.

10.

New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

van Dodewaard-de Jong JM, Verheul HMW, Bloemendal HJ, de Klerk JMH, Carducci MA, van den Eertwegh AJM.

Clin Genitourin Cancer. 2015 Aug;13(4):271-279. doi: 10.1016/j.clgc.2015.01.008. Epub 2015 Jan 21. Review.

PMID:
25704270
11.

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.

Payne H, Bahl A, Mason M, Troup J, De Bono J.

BJU Int. 2012 Sep;110(5):658-67. doi: 10.1111/j.1464-410X.2011.10886.x. Epub 2012 Mar 19.

12.

Progress in emerging therapies for advanced prostate cancer.

Oudard S.

Cancer Treat Rev. 2013 May;39(3):275-89. doi: 10.1016/j.ctrv.2012.09.005. Epub 2012 Oct 26. Review.

PMID:
23107383
13.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187
14.

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.

Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11. Review.

PMID:
23957948
15.

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.

PMID:
23587782
16.

Current therapeutic options in metastatic castration-resistant prostate cancer.

Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R.

Semin Oncol. 2018 Oct;45(5-6):303-315. doi: 10.1053/j.seminoncol.2018.10.001. Epub 2018 Oct 30. Review.

PMID:
30446166
17.

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy.

Gartrell BA, Saad F.

Ther Adv Urol. 2015 Aug;7(4):194-202. doi: 10.1177/1756287215592288. Review.

18.

Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.

Parente P, Parnis F, Gurney H.

Asia Pac J Clin Oncol. 2014 Sep;10(3):205-15. doi: 10.1111/ajco.12193. Epub 2014 Apr 3. Review.

PMID:
24750803
19.

Is there still a place for docetaxel rechallenge in prostate cancer?

Petrioli R, Francini E, Roviello G.

World J Clin Oncol. 2015 Oct 10;6(5):99-103. doi: 10.5306/wjco.v6.i5.99.

20.

Recent Advances in Prostate Cancer Treatment and Drug Discovery.

Nevedomskaya E, Baumgart SJ, Haendler B.

Int J Mol Sci. 2018 May 4;19(5). pii: E1359. doi: 10.3390/ijms19051359. Review.

Supplemental Content

Support Center